Introduction
============

Tuberculosis (TB) is still one of the major public health problems affecting more than 10 million people and causing 1.6 million deaths worldwide \[[@r1]\]. Since 1994, milestones of TB prevention and control have been the three World Health Organization (WHO) strategies Directly observed treatment short course (DOTS), Stop TB and End TB \[[@r2],[@r3]\]. Implementing the WHO strategies, many countries established between 2000 and 2014 the basic requirements for providing high-quality TB diagnosis and treatment \[[@r3]\]. Those strategies focused on case notification and monitoring of treatment outcome as the essential measures to evaluate the effectiveness of interventions and identify potential gaps in TB control \[[@r4]\]. The global target is to reach a treatment success rate (TSR) of at least 85% \[[@r2]\]. However, the WHO\'s post-2015 End TB Strategy aims for at least 90% \[[@r3]\]. TB disproportionately affects different segments of the population. Higher male-to-female ratio was reported in some studies and surveillance data as well as higher TB notification rate and lower mortality rate among males \[[@r1],[@r5],[@r6]\]. Changes in the occurrence of the disease by age, sex, education, anatomical site of the disease, history of previous treatment, HIV status and drug resistance are also important indicators of TB control programmes \[[@r7]-[@r11]\].

In the period 2005--15, Serbia almost became a country with a low TB burden, reducing TB notification rate from 32 per 100,000 in 2005 to 13 per 100,000 in 2015 by implementing the WHO DOTS and Stop TB strategies in the National Tuberculosis Programme with financial support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). An analysis of trends and differences in TB notification and treatment outcomes by sex, age, education, occupation, TB localisation and history of previous treatment has not yet been performed in Serbia. It may help improve our understanding of the performance of the TB control programme. Previous studies in Serbia have focused on trends in TB incidence and mortality and characteristics of TB among the elderly population \[[@r12]-[@r14]\]. However, these studies did not analyse factors associated with successful and unsuccessful treatment outcome, which could provide useful evidence for targeted evidence-based interventions. Therefore, the objective of this study was to assess the trends in TB notification, TB mortality rate and treatment success and to identify factors associated with treatment success, loss to follow-up and mortality among TB patients notified in Serbia in a period of 11 years.

Methods
=======

We performed retrospective trend analysis and analysis of treatment outcomes of all (n = 17,441) TB cases notified in Serbia in the period 2005--15 from all health facilities, based on the electronic data collection of the Ministry of Health and Institute of Public Health of Serbia. The electronic case-based data collection system in Serbia was introduced in 2005 with the support of the GFATM in line with the WHO TB notification form. Standard indicators from the WHO checklist S*tandards and benchmarks for TB surveillance and vital registration systems* were used to assess internal consistency of the data: changes over time in TB notification rate, the ratio between the number of notified pulmonary and extra-pulmonary TB cases, and the male-to-female ratio of TB cases \[[@r15]\].

To describe TB epidemiology in the country, we analysed notified TB cases by age, sex, education, occupation, anatomical site of the disease, history of previous treatment, HIV status (recorded since 2010) and multidrug resistance. Treatment results included: cured, treatment completed, defaulted (lost to follow-up), died, failed and not evaluated \[[@r16],[@r17]\]. National TB control guidelines for Serbia, in line with WHO guidelines, were used for TB diagnosis and case definition \[[@r16]\].

Tuberculosis diagnosis
----------------------

TB diagnosis was based on clinical and radiological findings and was confirmed bacteriologically and/or histologically. Laboratory confirmation was performed by detection of *Mycobacterium tuberculosis* complex from a clinical specimen, either by culture or by a newer molecular technique \[[@r18]\].

Case definition and classification
----------------------------------

*Pulmonary tuberculosis* (PTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree. PTB also includes cases that affect the lung with additional extra-pulmonary manifestations.

*Extra-pulmonary tuberculosis* (EPTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones or meninges.

*New patients* are defined as those who have never been treated for TB or have taken anti-TB drugs for less than 1 month.

*Previously treated* patients are defined as those who have received 1 month or more of anti-TB drugs in the past.

*Multidrug resistance* refers to resistance to at least isoniazid and rifampicin together.

Treatment outcomes were categorised according to the latest WHO definitions and reporting framework for tuberculosis \[[@r11]\].

Statistical analysis
--------------------

Descriptive statistics of trends of TB notification, TB mortality rates and treatment outcomes during the 11-year study period were performed for all PTB and EPTB cases. Population data for each year were obtained from the National Statistical Office \[[@r18]\]. We analysed trends of case notification by age, sex, education, occupation, anatomical site of the disease, history of previous treatment, HIV status and first-line drug susceptibility.

A logistic regression analysis was used to identify factors associated with treatment success, loss to follow-up and mortality. We used three separate models. The variables age, sex, education, occupation, anatomical site of the disease, history of previous treatment, HIV status and first-line drug susceptibility test (DST) were entered in each univariate logistic regression analysis (ULRA) model. For the first model, the outcome was dichotomised as treatment success (cured or completed) vs unsuccessful treatment (failed, died, lost to follow-up or not evaluated). For the second model, the outcome was dichotomised as lost to follow-up vs follow-up (treatment success, failed, died, or not evaluated). For the third model, the outcome was dichotomised as died vs not died (treatment success, failed, lost to follow-up or not evaluated).

The variables that showed statistically significant association at p value ≤ 0.05 in ULRA were entered in multivariable logistic regression analysis (MLRA) models. Data were analysed using the Statistical Package for Social Sciences (IBM SPSS) version 24 and p values ≤ 0.05 were considered statistically significant.

Ethical statement
-----------------

This study was approved by the Ethics Committee of the Institute of Public Health of Serbia (No 24/2016). Personal identifiers of TB cases were coded to maintain the confidentiality of the patient information before analysis, and patient records or information were anonymised and de-identified before analysis.

Results
=======

Internal consistency indicators
-------------------------------

The mean percentage of annual changes of TB notification rate from 2005 to 2015 was 8.25%. During the same period, the ratio of nationally notified PTB vs EPTB cases ranged from 6.04 to 8.09, with a slight decrease in PTB cases from 2013 to 2015. The male-to-female ratio of notified TB cases was generally consistent (range: 1.40--1.62), but there was a notable increase in the proportion of male cases over time.

Trends analysis of tuberculosis notifications
---------------------------------------------

The ТB notification rate for all forms of TB decreased significantly between 2005 and 2015, from 32 per 100,000 population in 2005 to 13 per 100,000 in 2015 ([Table 1](#t1){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}) (p value for trend \< 0.001). Likewise, we observed a significant decrease in the PTB notification rate, from 28 per 100,000 population in 2005 to 11 per 100,000 in 2015 (p value for trend \< 0.001), while there were no great variations in the EPTB notification rate (p value for trend \> 0.05). Over the observed period, male-to-female ratio and notification rates per age category remained unchanged (p value for trend \> 0.05).

###### Characteristics of notified tuberculosis cases, Serbia, 2005--2015 (n = 17,441)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics\                 2005    2006   2007    2008   2009    2010    2011    2012    2013    2014    2015    Total                                                                       
  -------------------------------- ------- ------ ------- ------ ------- ------- ------- ------- ------- ------- ------- ------- ------- ----- ------- ----- ------- ------- ------- ---- ----- ---- --------
  All cases                        2,378   14     2,170   12     2,063   12      1,831   10      1,712   10      1,523   9       1,379   8     1,228   7     1,217   7       1,051   6    889   5    17,441

  Sex                                                                                                                                                                                                

  Male                             1,444   61     1,328   61     1,256   61      1,110   61      1,045   61      915     60      834     60    758     62    753     62      607     58   541   61   10,591

  Female                           934     39     842     39     807     39      721     39      667     39      608     40      545     40    470     38    464     38      444     42   348   39   6,850

  Age category (years)                                                                                                                                                                               

  0--14                            20      1      24      1      29      1       22      1       21      1       17      1       13      1     18      1     14      1       21      2    8     1    207

  15--24                           180     8      169     8      143     7       148     8       135     8       138     9       96      7     101     8     93      8       77      7    57    6    1,337

  25--34                           258     11     234     11     206     10      183     10      162     9       146     10      151     11    143     12    136     11      101     10   113   13   1,833

  35--44                           340     14     283     13     294     14      244     13      238     14      226     15      167     12    170     14    172     14      173     16   126   14   2,433

  45--54                           465     20     441     20     432     21      371     20      299     17      260     17      272     20    220     18    201     17      159     15   169   19   3,289

  55--64                           338     14     289     13     308     15      306     17      300     18      244     16      258     19    223     18    219     18      192     18   156   18   2,832

  ≥ 65                             777     33     730     34     651     32      557     30      557     33      492     32      422     31    353     29    382     31      328     31   260   29   5,509

  Education                                                                                                                                                                                          

  High school or lower             2,291   96     2,057   95     1,944   94      1,732   95      1,622   95      1,442   95      1,294   94    1,164   95    1,156   95      975     93   812   91   16,489

  University or higher             87      4      113     5      119     6       99      5       90      5       81      5       85      6     64      5     61      5       76      7    77    9    952

  Occupation                                                                                                                                                                                         

  Unemployed                       220     9      262     12     304     15      292     16      311     18      316     21      285     21    304     25    303     25      200     19   161   18   2,958

  Employed                         2,158   91     1,908   88     1,759   85      1,539   84      1,401   82      1,207   79      1,094   79    924     75    914     75      851     81   728   82   14,483

  Anatomical site of the disease                                                                                                                                                                     

  PTB                              2,118   89     1,872   86     1,820   88      1,594   87      1,500   88      1,306   86      1,208   88    1,090   89    1,061   87      908     86   771   87   15,248

  EPTB                             260     11     298     14     243     12      237     13      212     12      217     14      171     12    138     11    156     13      143     14   118   13   2,193

  History of previous treatment                                                                                                                                                                      

  New patient                      2,118   89     1,884   87     1,772   86      1,567   86      1,502   88      1,343   88      1,240   90    1,090   89    1,093   90      952     91   800   90   15,361

  Previously treated               260     11     286     13     291     14      264     14      210     12      180     12      139     10    138     11    124     10      99      9    89    10   2,080

  HIV status^a^                                                                                                                                                                                      

  Known                            NA      NA     NA      NA     NA      4       0       67      5       95      8       118     10      124   12      90    10      498                             

  Positive                         NA      NA     NA      NA     NA      4       0       6       0       4       0       17      1       8     1       4     0       43                              

  Unknown                          NA      NA     NA      NA     NA      1,515   99      1,306   95      1,129   92      1,082   89      919   87      795   89      6,746                           

  Multidrug resistance                                                                                                                                                                               

  No                               181     8      592     27     865     42      973     53      1,074   63      1,092   72      954     69    863     70    811     67      674     64   508   57   8,587

  Yes                              15      1      15      1      33      2       15      1       11      1       13      1       7       1     7       1     8       1       11      1    5     1    140

  Unknown                          2,182   92     1,563   72     1,165   56      843     46      627     37      418     27      418     30    358     29    398     33      366     35   376   42   8,714
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EPTB: Extra-pulmonary tuberculosis; NA: not available; PTB: pulmonary tuberculosis.

^a^ Data on HIV status are available in the TB register from 2010 \[[@r19]\].

![Trends in tuberculosis notification rates per 100,000 population by year and by anatomical site of the disease, Serbia, 2005--2015 (n = 17,441)](1900322-f1){#f1}

The proportions of multidrug-resistant TB cases remained stable at 1--2% over time (p value for trend \> 0.05). The proportions of negative DST results increased significantly from 7.6% in 2005 to 57.1% in 2015. There was also a significant decrease in unknown DST results from 91.7% in 2005 to 42.3% in 2015 (p value for trend \< 0.05).

The proportions of HIV-positive TB cases remained stable in the period from 2010 to 2015 (p value for trend \> 0.05), while the proportions of HIV-negative results increased significantly (p value for trend \< 0.05), from 0.3% in 2010 to 10.1% in 2015.

Trends in treatment outcomes
----------------------------

Among the 17,441 notified cases, treatment outcome was available for 17,388. Over the 11-year period, there were no significant changes in the treatment outcomes of drug-susceptible TB ([Table 2](#t2){ref-type="table"}). Treatment success slightly increased among all new TB cases (p value for trend \> 0.05), from 83% in 2005 to 84% in 2015, while it slightly decreased among retreatment cases (p value for trend \> 0.05), from 70% in 2005 to 67% in 2015. Among new cases, the increase in treatment success was slightly higher among EPTB cases (p value for trend \> 0.05), from 85% in 2005 to 90% in 2015. The proportion of patients lost to follow-up decreased slightly, from 6% in 2005 to 5% in 2015 among all new cases (p value for trend \> 0.05) and from 14% in 2005 to 13% in 2015 among retreatment cases (p value for trend \> 0.05).

###### Treatment outcomes among tuberculosis cases, Serbia, 2005--2015 (n = 17,388)

  Treatment outcome                 2005    2006    2007    2008    2009    2010    2011    2012    2013    2014   2015    Total                                                             
  --------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------ ------- -------- ------- ---- ----- ---- ----- ---- ----- ---- ----- ---- --------
  New pulmonary TB                                                                                                                                                                           
  Cured + completed                 1,541   82      1,330   83      1,305   85      1,164   85      1,122   86     981     86       912     84   784   82   751   79   659   80   574   83   11,123
  Lost to follow-up                 118     6       95      6       71      5       79      6       62      5      54      5        50      5    52    5    56    6    34    4    37    5    708
  Died                              105     6       115     7       106     7       93      7       82      6      77      7        96      9    90    9    87    9    90    11   56    8    997
  Failed                            15      1       21      1       19      1       27      2       15      1      10      1        5       0    7     1    10    1    7     1    9     1    145
  Not evaluated                     94      5       47      3       41      3       12      1       24      2      17      1        17      2    24    3    43    5    37    4    16    2    372
  Total                             1,873   1,608   1,542   1,375   1,305   1,139   1,080   957     947     827    692     13,345                                                            
  New extra-pulmonary TB                                                                                                                                                                     
  Cured + completed                 216     88      244     88      211     92      199     94      177     79     184     90       140     88   109   82   119   82   118   84   106   93   1,823
  Lost to follow-up                 12      5       15      5       10      4       8       4       8       4      8       4        5       3    16    12   9     6    6     4    6     5    103
  Died                              10      4       9       3       8       3       3       1       3       1      6       3        12      8    5     4    8     5    9     6    1     1    74
  Failed                            0       0       0       0       0       0       0       1       1       0      2       1        0       0    0     0    1     1    0     0    0     0    4
  Not evaluated                     7       3       8       3       1       0       1       0       35      16     4       2        3       2    3     2    9     6    7     5    1     1    79
  Total                             245     276     230     211     224     204     160     133     146     140    114     2,084                                                             
  All new TB cases                                                                                                                                                                           
  Cured + completed                 1,757   83      1,574   84      1,516   86      1,363   86      1,299   85     1,165   87       1,052   85   893   82   870   80   777   80   680   84   12,946
  Lost to follow-up                 130     6       110     6       81      5       87      5       70      5      62      5        55      4    68    6    65    6    40    4    43    5    811
  Died                              115     5       124     7       114     6       96      6       85      6      83      6        108     9    95    9    95    9    99    10   57    7    1071
  Failed                            15      1       21      1       19      1       28      2       16      1      12      1        5       0    7     1    11    1    7     1    9     1    150
  Not evaluated                     101     5       55      3       42      2       13      1       59      4      21      2        20      2    27    2    52    5    44    5    17    2    451
  Total                             2,118   1,884   1,772   1,587   1,529   1,343   1,240   1,090   1,093   967    806     15,429                                                            
  Previously treated cases                                                                                                                                                                   
  Cured + completed                 174     70      187     76      202     72      174     73      154     75     125     77       106     79   95    70   87    71   65    64   58    67   1,427
  Lost to follow-up                 34      14      25      10      46      16      20      8       26      13     17      10       12      9    22    16   13    11   13    13   11    13   239
  Died                              26      10      24      10      23      8       29      12      19      9      16      10       9       7    13    10   8     7    11    11   10    12   188
  Failed                            6       2       1       0       7       2       1       0       0       0      2       1        3       2    2     1    4     3    0     0    3     3    29
  Not evaluated                     8       3       8       3       4       1       13      5       6       3      2       1        5       4    3     2    11    9    12    12   4     5    76
  Total                             248     245     282     237     205     162     135     135     123     101    86      1,959                                                             
  Multidrug-resistant TB cases^a^                                                                                                                                                            
  Cured + completed                 NA      NA      NA      NA      11      55      13      76      12      71     4       57       9       75   8     89   4     80   61                    
  Lost to follow-up                 NA      NA      NA      NA      1       5       1       6       2       12     0       0        1       8    0     0    1     20   6                     
  Died                              NA      NA      NA      NA      6       30      2       12      2       12     2       29       2       17   1     11   0     0    15                    
  Failed                            NA      NA      NA      NA      2       10      0       0       1       6      1       14       0       0    0     0    0     0    4                     
  Not evaluated                     NA      NA      NA      NA      0       0       1       6       0       0      0       0        0       0    0     0    0     0    1                     
  Total^b^                          NA      NA      NA      NA      20      17      17      7       12      9      5       87                                                                

MDR: multidrug-resistant; NA: not available; TB: tuberculosis.

^a^ Treatment outcome of MDR TB cases is available in the TB register from 2009, the year when organised MDR TB treatment started in Serbia.

^b^ The number of laboratory-confirmed MDR TB cases enrolled in second-line TB treatment. The difference between registered patients and patients enrolled in treatment is due to backlog of patients from previous years.

The ТB mortality rate for all forms of TB was twice reduced between 2005 and 2015, from 1.91 per 100,000 population in 2005 to 0.89 per 100,000 in 2015 ([Figure 2](#f2){ref-type="fig"}) (p value for trend \< 0.05). This was due to a significant decrease in PTB mortality rate, from 1.70 per 100,000 population in 2005 to 0.77 per 100,000 in 2015 (p value for trend \< 0.05), while there was no great variation in EPTB mortality rate (p value for trend \> 0.05).
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Treatment success rate of multidrug-resistant (MDR) TB cases increased significantly from 55% in 2009 to 80% in 2015 (p value for trend \< 0.05). These data correspond to the period 2009--15, because organised treatment of MDR TB in Serbia started in 2009 ([Table 2](#t2){ref-type="table"}).

Characteristics of the cases
----------------------------

Of the 17,441 cases, 6,850 (39.3%) were women and 10,591 (60.7%) were men, yielding a male-to-female ratio of 1.5∶1. The mean age for all cases was 46 years (standard deviation (SD): 17), 44 years for men (SD: 16) and 49 years for women (SD: 18) years. Most of the cases, 15,248 (87.4%), had PTB while 2,193 (12.6%) had EPTB. A total of 16,489 (94.5%) cases had finished high school or a lower level of education, whereas 952 (5.5%) had completed university level or higher. Most of the cases were employed (n = 14,483; 83.0%). Most were new cases (n = 15,361; 88.0%), while 2,080 (12.0%) were previously treated ([Table 1](#t1){ref-type="table"}). There were 140 (1.7%) notified and recorded MDR cases among 8,437 cases (48.4%) covered by DST, while for 9,004 cases (51.6%), DST results were unknown ([Table 1](#t1){ref-type="table"}).

Data on HIV status have been recorded in the TB register since 2010 and 7,287 TB cases were notified in the period from 2010 to 2015. There were 43 (7.9%) notified HIV-positive cases among 541 tested and recorded, while for 6,746, the HIV status was unknown.

MDR TB cases were included in each of the three univariate models. The variables that showed a statistically significant association at p value ≤ 0.05 in ULRA were entered in multivariable models. MDR TB was not statistically significantly associated with treatment success (model 1), loss to follow-up (model 2) or mortality (model 3) and was therefore not included in the models of MLRA.

Factors associated with treatment outcomes
------------------------------------------

In the multivariable logistic regression analysis ([Table 3](#t3){ref-type="table"}), factors associated with treatment success were: new TB (OR = 2.05; 95% CI: 1.86--2.27), female sex (OR = 1.41; 95% CI: 1.30--1.51), age below 65 years (OR = 1.61; 95% CI: 1.49--1.74), university or higher level of education (OR = 1.62; 95% CI: 1.23--1.88) and EPTB (OR = 1.53; 95% CI: 1.36--1.74). A higher risk of being lost to follow-up was associated with previous TB treatment (OR = 2.38; 95% CI: 2.08--2.77), male sex (OR = 1.57; 95% CI: 1.39--1.79), age below 65 years (OR = 1.37; 95% CI: 1.20--1.51), high school or lower level of education (OR = 2.57; 95% CI: 1.74--3.80) and PTB (OR = 1.28; 95% CI: 1.06--1.56). In addition, a higher risk of TB mortality was related to previous TB treatment (OR = 1.39; 95% CI: 1.12--1.61), male sex (OR = 1.34; 95% CI: 1.19--1.52), age 65 years and above (OR = 4.34; 95% CI: 4.00--5.00), high school or lower level of education (OR = 1.63; 95% CI: 1.14--2.33) and PTB (OR = 2.24; 95% CI: 1.78--2.83).

###### Factors associated with treatment success, loss to follow-up and mortality among notified tuberculosis cases, multivariable logistic regression analysis, Serbia, 2005--2015 (n = 17,441)

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                               Treatment success   Lost to follow-up   Mortality                                       
  --------------------------------------------- ------------------- ------------------- ------------------- ------- ------------------- -------
  Sex: male\                                    0.71 (0.66--0.77)   0.000               1.57 (1.39--1.79)   0.000   1.34 (1.19--1.52)   0.000
  (Ref: female)                                                                                                                         

  Age category: 0--64 years\                    1.61 (1.49--1.74)   0.000               1.37 (1.20--1.51)   0.000   0.23 (0.20--0.25)   0.000
  (Ref: ≥ 65 years)                                                                                                                     

  Education: high school or lower\              0.66 (0.53--0.81)   0.000               2.57 (1.74--3.80)   0.000   1.63 (1.14--2.33)   0.000
  (Ref: university or higher)                                                                                                           

  Occupation: Unemployed\                       0.91 (0.80--1.03)   0.141               1.10 (0.92--1.31)   0.279   1.08 (0.89--1.31)   0.403
  (Ref: employed)                                                                                                                       

  Anatomical site of the disease: PTB\          0.65 (0.57--0.73)   0.000               1.28 (1.06--1.56)   0.010   2.24 (1.78--2.83)   0.000
  (Ref: EPTB)                                                                                                                           

  History of previous treatment: new patient\   2.05 (1.86--2.27)   0.000               0.42 (0.36--0.48)   0.000   0.73 (0.62--0.86)   0.000
  (Ref: retreatment)                                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; EPTB: Extra-pulmonary tuberculosis; OR: odds ratio; PTB: pulmonary tuberculosis; Ref: reference value.

Discussion
==========

From 2005 to 2015 in Serbia, annual changes in the TB notification rate were less than 10%. The ratio of PTB to EPTB cases notified nationally ranged from 6.04 to 8.09, with a slight decrease in PTB cases from 2013 to 2015, suggesting that these data were internally consistent \[[@r16]\]. The male-to-female ratio increasing over time may suggest women were less likely in the later years than in the earlier years to seek healthcare and/or were underdiagnosed when they did seek care. In addition, it may indicate that epidemiologically, there was a real increase in men (or decrease in women) who developed TB \[[@r20]\].

Over the 11-year study period, we found a decrease in TB notification and mortality rates and a stable trend in treatment outcomes and notification rates per age category, education, occupation, anatomical site of the disease and history of previous treatment. The dominant proportion of male TB cases corresponds to the global surveillance data \[[@r1]\] and surveillance data for Europe \[[@r5]\], with the male-to-female ratio ranging from 1.5∶1 to 2∶1.

We found that the proportion of PTB among TB patients in our study was 20% higher than the proportion of PTB among TB patients globally \[[@r1]\] and in the European Union/European Economic Area (EU/EEA) \[[@r5]\]. Solovic et al. reported that the percentage of EPTB cases in the EU/EEA) in 2011 ranged from 4% to 48% \[[@r21]\]. The differences may be explained by different risk factors for EPTB or by diagnostic challenges as EPTB can manifest with a variety of symptoms. Low levels of suspicion of clinicians as well as difficulties in obtaining adequate samples for confirmation are also reported as a challenge in EPTB diagnosis \[[@r21]\]. In addition, some of the reasons for higher proportion of PTB in Serbia compared with EU/EEA countries could be due to low HIV prevalence in Serbia \[[@r22]\] and to the dominant proportion of men among TB patients as there is evidence that the incidence of EPTB is likely to be higher among women than men \[[@r23]\].

We found that the proportion of previously treated cases was 20 percentage points lower in Serbia than globally \[[@r1]\]. This could indicate good implementation of the DOTS strategy, good case management, low burden of drug-resistant TB, good adherence to treatment or good access to and availability of TB services \[[@r2]\]. We assume that reliability of the data can be considered satisfactory because TB case definitions are clearly laid out in the guidelines for TB doctors as a part of routine TB training in the country and are consistent with the WHO guidelines. Firstly, TB cases are usually classified at the moment of filling out the TB notification form, by a physician who diagnosed TB based on medical investigations and medical records. Data from the TB notification form are further validated at the regional level by epidemiologists and pulmonologists before they are entered into a case-based electronic data collection system. A third round of data quality control is usually performed at the central (national) level in the form of automatic checks for duplicates, missing records and consistency during the process of data cleaning before data analysis; the central level receives copies of all case-based TB notification forms.

Educational status of TB patients in our study was lower than in the general population in Serbia \[[@r24]\]. There were no data on educational status of TB patients in Europe. Nevertheless, a large body of scientific evidence supports education as an important determinant of health and indicates that lower education is associated with poor health, stress and lower self-esteem \[[@r25]\]. The majority of patients in our study were employed. In most European countries, there is a greater share of unemployment among TB patients \[[@r26]\].

The proportion of HIV-positive TB cases was consistent with reports from the Balkan countries (excluding Romania with significantly higher TB/HIV prevalence) \[[@r1],[@r27]\] and lower than in other EU/EEA countries \[[@r5]\]. Studies conducted in Africa and Asia found a much higher prevalence of HIV infection among TB patients (30--38%) \[[@r28],[@r29]\]. The slight increase in the proportion of HIV-positive TB cases observed in Serbia was due to implementation of the WHO policy on collaborative TB/HIV activities and increased HIV testing of TB patients. However, among drug users, homeless people, prisoners and alcoholics, the proportion of TB cases with known HIV status is still very low in Serbia compared with EU/EEA countries (68%) because HIV testing is not routinely offered to all TB patients. There is a need for continuous training of all medical and non-medical workers who deal with TB and HIV infection and for a joint TB/HIV communication and social mobilisation strategy \[[@r5],[@r30]\]. Implementation of the WHO Stop TB strategy resulted in an increased DST coverage, in line with the EU countries \[[@r5]\]. Given that the latest WHO End TB strategy target is 100% DST coverage, this is a programmatic challenge to be addressed in the coming years. We identified very small percentages of notified TB cases among children (0.8--2% of notified cases per year were children aged 0--14 years) in relation to WHO standards and benchmarks for childhood TB (5--15%) for middle-income countries where Serbia belongs \[[@r20]\]. This result pointed to under-reporting because of limited sensitivity of surveillance system as well as limited capacities of the TB programme to diagnose childhood TB.

The treatment success rate in Serbia was higher than the EU treatment success rate \[[@r5]\] but still below the global target of 90% \[[@r3]\]. The minor improvements during the study period could be attributed to better overall case management (early diagnosis and treatment, reduction in loss to follow-up and mortality). Other possible reasons could be community-based patient support interventions which improved access to and use of TB control services and decreased the proportion of non-evaluated cases compared with previous years \[[@r3]\].

We identified previous TB treatment, male sex, lower level of education and PTB as independent predictors of loss to follow-up and mortality, consistent with many other studies \[[@r29],[@r31]\]. Some studies identified unemployment \[[@r32]\] and migration \[[@r33]\] as predictors of loss to follow-up caused by poor adherence to treatment. Although there were no foreign-born cases registered in our study, there is a possibility of under-reporting because of the lack of a sensitive surveillance system. Authors from the United Kingdom accentuated the public health implications of patients lost to follow-up, who may contribute to ongoing disease transmission and the risk of drug resistance \[[@r32]\]. Patients with severe forms of extra-pulmonary disease may be less likely to become lost, because they are likely to be in closer contact with the healthcare provider and may be hospitalised \[[@r34]\]. Weaknesses in the health system, such as lack of updated clinical guidelines, non-compliance of healthcare professionals with the guidelines, interruptions in drug supply or poor training, supervision and organisation of TB programmes, have also been identified as factors contributing to the poor management of patients, resulting in treatment interruptions and loss to follow-up \[[@r2],[@r23]\].

We found age 65 years and above to be an independent predictor of TB mortality. Many studies reported higher mortality rates among elderly people \[[@r4],[@r12]\]. Co-morbidities among elderly people influence the reactivation of previously acquired TB disease by reducing the immunity. Moreover, immunocompromised patients are more likely to develop severe disseminated forms of TB disease and adverse drug reactions \[[@r12],[@r34]\]. Delay in diagnosis and treatment among older age groups was also identified, which could increase the risk of death. In addition, we identified age below 65 years as predictor of loss to follow-up. Patients younger than 65 years are more likely to be immunocompetent, with fewer co-morbidities. Loss to follow-up among this group of patients may be related to social barriers and perception of stigma. TB is known to be a highly stigmatised disease and many studies have identified stigma as an obstacle in cooperation and communication with the health service, resulting in delayed seeking of medical help, and an obstacle during treatment, leading to interruptions, failure, recurrence and drug resistance \[[@r34],[@r35]\].

Limitations
-----------

We could not distinguish between deaths that were due to TB or deaths that were due to other diseases during TB treatment because this information was not available. It was not possible to investigate other factors associated with TB treatment outcomes, such as socioeconomic factors, tobacco use, drug or alcohol abuse, other co-morbidities or homelessness. Data on DST results were missing for half of the cases, some of whom may have had MDR TB. Despite its limitations, our study provides evidence on the risk factors associated with TB treatment outcomes in Serbia. Further analyses are needed to explore further associations.

Conclusions
===========

In order to improve performance of the TB programme in Serbia, it is necessary to address groups at risk of poor treatment outcomes. To prevent loss to follow-up and mortality and to achieve better adherence to treatment, case management has to be improved towards providing holistic patient-centred inter-sectoral interventions and support during treatment. It is important to update the national TB prevention and control strategy and to revise existing guidelines in line with the available scientific evidence, so as to increase coverage of DST and HIV testing and improve early detection of HIV co-infection and drug resistance, the main obstacles in modern TB control.
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